Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers

10.1371/journal.pone.0153095

10.1016/B978-0-08-045031-5.00003-7

10.1126/science.270.5237.819

10.1016/0092-8674(91)90035-W

10.1002/mus.20349

10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T

10.1083/jcb.122.4.809

McNally, 1996, Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation, Am J Hum Genet, 59, 1040

10.1093/hmg/5.11.1841

10.1016/j.nurt.2008.08.003

10.1016/0092-8674(87)90579-4

Koenig, 1989, The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion, Am J Hum Genet, 45, 498

10.1016/0888-7543(88)90113-9

10.1016/0960-8966(92)90025-2

10.1016/0022-510X(90)90195-S

10.1016/0960-8966(93)90109-W

10.1038/nrd3625

10.1111/j.1440-1681.2006.04403.x

10.1016/S0140-6736(11)60756-3

10.1056/NEJMoa1011367

10.1002/ana.23982

10.1016/S1474-4422(14)70195-4

10.1089/nat.2016.0657

10.1089/nat.2017.0665

Clayton, 2014, Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease, Mol Ther Nucleic Acids, 3, 10.1038/mtna.2014.57

10.1002/emmm.201202168

10.15252/emmm.201505047

10.1002/humu.22931

10.1172/JCI85908

10.1172/JCI82768

Morcos, 2008, Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues, BioTechniques, 45, 613, 10.2144/000113005

10.1093/hmg/ddn151

10.1093/hmg/7.7.1083

10.1093/hmg/10.15.1547

10.1016/S0960-8966(99)00010-3

10.1007/978-1-61779-767-5_8

10.1016/j.mcn.2013.04.005

Kim, 2016, Direct reprogramming of urine-derived cells with inducible MyoD for modeling human muscle disease, Skelet Muscle, 6, 10.1186/s13395-016-0103-9

10.1161/CIRCULATIONAHA.117.028382

10.1093/nar/gkw533

10.1083/jcb.143.7.2033

10.1016/j.yexcr.2006.01.024

10.1002/mus.10566

10.1093/nar/gkg595

10.1002/jgm.838

10.1002/jgm.1288

10.1016/j.nmd.2006.05.017

10.1016/j.coph.2005.07.001

10.1093/nar/gkp215

10.1083/jcb.142.5.1279

10.1073/pnas.1204638109

10.1002/ana.21627

10.1038/nm.3765

Sardone, 2017, Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease, Molecules, 22, 10.3390/molecules22040563

Flicek, 2013, Ensembl 2013, Nucleic Acids Res, 41, D48

10.1016/j.cell.2010.12.031

10.1152/japplphysiol.01366.2009